改良自控病例系列分析:美国65岁及以上Medicare受益人接种新冠疫苗基础免疫后死亡风险
本研究采用改良自控病例系列方法,基于美国Medicare按服务收费理赔数据,分析2020年12月14日至2021年8月11日期间65岁及以上受益人接种新冠疫苗基础免疫后28天内的非新冠死亡风险。共纳入188,948例接种后死亡。结果显示所有基础免疫剂次的相对发病比均显著小于1,未观察到接种后4周内死亡风险增加。
要点
- 美国65岁及以上Medicare受益人接种新冠疫苗基础免疫后28天内非新冠死亡风险未增加。
- BNT162b2第1剂和第2剂相对发病比分别为0.63和0.67,均显著小于1。
- mRNA-1273和Ad26.COV2·S各剂次相对发病比同样显著小于1,次要死亡结局结果相似。
核心结论
- 美国65岁及以上成年人在接种新冠疫苗基础免疫剂次后4周内未观察到死亡风险增加。
研究设计与样本
- 研究采用改良自控病例系列设计,使用Medicare按服务收费理赔与参保数据。
- 纳入2020年12月14日至2021年8月11日期间65岁及以上受益人接种后死亡,共188,948例符合分析条件。
- 暴露包括接种最多2剂BNT162b2或mRNA-1273,或1剂Ad26.COV2·S。
- 风险区间为接种后前28天,对照区间为剩余观察期,采用伪似然法估计相对发病比。
主要发现
- 所有基础免疫剂次的非新冠死亡相对发病比均显著小于1。
- BNT162b2第1剂相对发病比为0.63(95%CI:0.62,0.65),第2剂为0.67(95%CI:0.66,0.68)。
- mRNA-1273第1剂相对发病比为0.52(95%CI:0.50,0.53),第2剂为0.63(95%CI:0.61,0.64)。
- Ad26.COV2·S第1剂相对发病比为0.60(95%CI:0.55,0.65)。
- 三个次要死亡结局观察到相似的相对发病比。
临床怎么用
- 为老年人新冠疫苗接种的安全性提供真实世界证据,支持基础免疫接种不增加短期死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies have attempted to perform self-controlled case series (SCCS) analyses to determine mortality risk following a primary series dose of a COVID-19 vaccine, including those conducted by the Florida Department of Health and the Vaccine Safety Datalink. We replicated these analyses to assess mortality risk post-vaccination in U.S. older adults. METHODS: Using Medicare Fee-for-Service claims and enrollment data, we identified post-vaccination deaths among beneficiaries aged ≥65 years from December 14, 2020, to August 11, 2021. Exposures included receipt of up to 2 doses of BNT162b2 or mRNA-1273 or 1 dose of Ad26.COV2·S. We estimated brand- and dose-specific relative incidence (RI) of non-COVID-19-related mortality and 3 secondary mortality outcomes. The risk interval was the first 28 days post-vaccination, and the control interval was the remaining observation period. To account for curtailed follow-up time after death, we included beneficiaries' planned observation time and used a pseudo-likelihood method to estimate RI. Deaths among the unvaccinated were included in the SCCS model to adjust for temporal effects of vaccinations and mortality. RESULTS: By August 11, 2021, there were 188,948 post-vaccination deaths eligible for SCCS analysis. RIs for non-COVID-19-related deaths were significantly less than 1 across all primary series doses. BNT162b2 Dose 1 and Dose 2 RI estimates were 0.63 (95% confidence interval (CI): 0.62, 0.65) and 0.67 (95% CI: 0.66, 0.68), respectively. mRNA-1273 Dose 1 and Dose 2 RI estimates were 0.52 (95% CI: 0.50, 0.53) and 0.63 (95% CI: 0.61, 0.64), respectively. Ad26.COV2·S Dose 1 RI estimate was 0.60 (95% CI: 0.55, 0.65). Similar RIs were observed for the secondary mortality outcomes. CONCLUSIONS: We did not observe an increased risk of mortality in U.S. older adults 4 weeks following a primary series dose of a COVID-19 vaccine.
引用
- McEvoy R, Hervol JR, Zhang Y, et al. A modified self-controlled case series on mortality risk following primary series doses of COVID-19 vaccines in U.S. Medicare beneficiaries aged 65 years and older. Vaccine. 2026. PMID: 41825195. doi:10.1016/j.vaccine.2026.128460
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。